

NON-CONFIDENTIAL OVERVIEW

NON-CONFIDENTIAL | NOVEMBER 2021



FORWARD LOOKING STATEMENT

Statements in this presentation may be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate", "believe", "estimate", "intend", "projection" and similar expressions, as they relate to the Company or its management, identify forward looking statements. These statements are based on current expectations, estimates and projections about the Company's business, based, in part, on assumptions made by the management. These statements are not a guarantee of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward looking statements due to numerous factors, including those described above and those risks discussed from time to time in AGENTIX's filings with the Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to: (i) our ability to integrate our operating partners into the Company's own projects, operations and commercialization (ii) product demand, market and customer acceptance of the Company's products, (iii) the Company's ability to obtain financing to expand operations and acquire assets, (iv) the Company's ability to attract qualified sales representatives, (v) competition, pricing and development difficulties, (vi) the Company's ability to conduct the business of AGENTIX, the contemplated business of any subsidiaries, if there are changes in laws, regulations, or government policies related to cannabinoids, (vii) general industry and market conditions and growth rates and general economic conditions. Any forward-looking statements speak only as of the date of which they are made, and the Company does not undertake any obligation to update any forward-looking statement to reflect event circumstances after the date of this presentation. Information on AGENTIX's website does not constitute a part of this presentation.

The information provided in this presentation is not intended to and shall not be construed as an offer to sell or a solicitation of an offer to buy any securities of AGENTIX. Offers to purchase our securities in a financing transaction, if and when made, will be made solely to a limited number of accredited investors in a private placement exempt from the registration requirements under the Securities Act of 1933, as amended.




FOCUS

Treatment of Metabolic Diseases

- Agentix is a clinical-stage biotechnology company developing therapeutic agents for the treatment of metabolic disease.
 - Type 2 diabetes mellitus
 - o **Obesity**
 - Non-alcoholic fatty liver disease (NAFLD)
 - Non-alcoholic steatohepatitis (NASH)
- Portfolio of novel peripherally-acting small molecule therapeutic agents.

- Predisposing factors:
- Obesity/overweightHigh calorie/high
- carbohydrate diet
- Sedentary lifestyle
- Sleep apnoeaGut dysbiosis
- Epigenetic and genetic influences




Endocrinology, Diabetes & Metabolism, Volume: 3, Issue: 4, First published: 24 February 2020, DOI: (10.1002/edm2.112)



THERAPEUTIC STRATEGY

Modulation of the Endocannabinoid System

- Key regulatory system of metabolism
- Acts through two receptors: CB1 & CB2
- **Blockade of Peripheral CB1 Receptor** lacksquare
 - Sustained weight loss
 - Control of glucose and lipid metabolism
 - Improved insulin control
 - Modulation of gastrointestinal function



Role of the Endocannabinoid System in Management of Patients with Type 2 Diabetes Mellitus and Cardiovascular Risk Factors; Stephen N. Davis, MD, FRCP & Jennifer M. Perkins, MD; AACE Endocrine Practice Volume 13, ISSUE 7, P790-804, November 01, 2007




THERAPEUTIC STRATEGY

Restrict Therapeutic Activity to the Periphery

Eliminate or Minimize **Diffusion Transport Across Blood-Brain Barrier**

Eliminate or Minimize Active Transport Across Blood-Brain Barrier



Wikimedia Commons; Schematic sketch showing the transport types at the blood-brain barrier by Armin Kübelbeck; November 13, 2011



CLINICAL PIPELINE

Indications targets are robust opportunities

Pipeli	ine Asset	Preclinical	GMP Manufacturing	Phase 1	Phase 2
AGTX-2004	Type 2 Diabetes				
	Obesity				
	Prader-Willi Associated Obesity				
AGTX-2003	NAFLD				
	NASH				



AGENTIX DEVLOPMENT PARTNERS





National Health Research Institutes (NHRI) is a Taiwanese government organization with a mandate to provide comprehensive medical research including drug development.



Research Triangle Institute (RTI) is a non-profit organization with drug discovery specialized consulting services to enable the complete development of pharmaceuticals.



A solution provider for pharmaceutical and biotechnology companies, Chemveda provides active pharmaceutical ingredient development services with an emphasis on producing efficiencies for global clientele.






AGTX-2004 & AGTX-2003



AGTX-2004 PHARMACOLOGY


Blood-Brain Barrier Penetration

- Peripherally restricted
- No significant brain penetration
- Higher affinity for CB1 receptor than Rimonabant



Daily oral dosing AGTX-2004 (PO, vehicle: DMSO/Tween 80/water, 1/1/8) R = 10mg/kg Rimonabant; = 20mg/kg AGTX-2004; = 10mg/kg AGTX-2004; = 3mg/kg AGTX-2004Data courtesy NHRI Taiwan

Hung, Ming-Shiu, et al, J. Med. Chem. 2013, 56, 9920–9933 Hung, Ming-Shiu, et al, Bioorganic & Medicinal Chemistry 27 (2019) 216–223



AGTX-2004^[F18] PET scan coronal cross section image at 90 min post injection.

- Deep blue (liver), cyan blue (heart), green (thigh muscle), pink (kidney), yellow (brain).
- Injection dose 170 μCi/0.15 mL (1.57×10⁻¹⁰ mol).





AGTX-2004 PRECLINICAL EFFICACY

Improved Insulin Resistance in DIO Mouse Model

Improved Glycemic Control







Daily oral dosing AGTX-2004 (PO, vehicle: DMSO/Tween 80/water, 1/1/8) R = Rimonabant; STD = BALB Mouse; DIO = Diet Induce Obese Mouse Data courtesy NHRI Taiwan


AGENTIX


AGTX-2004 PRECLINICAL EFFICACY

Induced Weight Loss and Improved Hepatic Steatosis in DIO Mouse Model


Reduces Weight Gain








Plasma Triglycerides



- ____ control
- ——— Rimonabant (10mg/kg)
- AGTX (3mg/kg)
- ---- AGTX (10mg/kg)
- AGTX (20mg/kg)
- -B-STD control

Day




A G E N T I X

AGTX-2003 PHARMACOLOGY

Blood-Brain Barrier Penetration

- Peripherally restricted
- No significant brain penetration
- Inverse agonism demonstrated

Pharmacokinetic study (single dose)	2500 J
Mouse PK (C57BL6) PO 0.3mg/kg – 1% NMP/CMC Plasma CMax: 940 ng/mL Brain CMax: 10 ng/mL	e Cuits
Liver CMax: 340 ng/mL (36%) Brain / Plasma CMax: 0.011 Half Life: 11 h	eo (w 1500- SEW)
Clearance: 21 mL/h/kg	Arbitrary Fluore (Mean ± 000
Rat PK (SD) PO 1mg/kg – 1% NMP/CMC	• <u> </u>
Plasma CMax: 3490 ng/mL Brain CMax: 46 ng/mL Liver CMax: 1020 ng/mL (29%)	u Soo- - Arpit - Arpit - Arpit
Brain / Plasma CMax: 0.014	0+
Half Life: 9.9 h Clearance: 18 mL/h/kg	-4



Amato, G. et al, Journal of Medicinal Chemistry 2019, 62 (13), 6330 - 6345




AGTX-2003 PRECLINICAL EFFICACY

DIO Mouse Model

AGTX-2003

 significantly
 reduces liver
 steatosis at
 1 mg/kg




Maitra, R. et al, ACS Pharmacol. Transl. Sci. 2021, 4, 757–764





AGTX-2003 PRECLINICAL EFFICACY

DIO Mouse Model

 AGTX-2003 decreases gene expression associated with hepatic lipid regulation, hepatic steatosis, and NASH.







Maitra, R. et al, ACS Pharmacol. Transl. Sci. 2021, 4, 757–764



COMPETITIVE LANDSCAPE

MOLECULE	COMPANY	BRAND	SMALL MOLECULE	NOVEL MoA	TARGET CB1	PERIPHERALLY RESTRICTED	CLINICAL STAGE	ORALLY DELIVERED	PEDIATRIC & ADULT PATIENTS	T2D	OBESITY	NAFLD / NASH
AGTX-2004	Agentix	TBD	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	✓	\checkmark	\checkmark	\checkmark
AGTX-2003		TBD	\checkmark	\checkmark	\checkmark	\checkmark	×	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark
INV-101		TBD	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	×	x	\checkmark
INV-202	– Inversago	TBD	\checkmark	\checkmark	\checkmark	\checkmark	×	\checkmark	\checkmark	×	x	×
GFB-024	Goldfinch Bio	TBD	×	\checkmark	\checkmark	\checkmark	\checkmark	×	×	×	x	×
MRI-1867	Scopus Biopharma	TBD	\checkmark	\checkmark	\checkmark	\checkmark	×	\checkmark	×	×	×	×
nimacimab	Bird Rock Bio	TBD	×	\checkmark	\checkmark	\checkmark	\checkmark	×	×	×	×	\checkmark
efruxifermin	Akero	TBD	×	\checkmark	×	\checkmark	\checkmark	×	×	×	×	\checkmark
ALT-801	Altimmune	TBD	×	\checkmark	×	\checkmark	\checkmark	×	×	×	×	\checkmark
LX2761	Lexicon	TBD	\checkmark	\checkmark	×	\checkmark	\checkmark	\checkmark	×	\checkmark	×	×
tirzepatide	Lilly	TBD	×	\checkmark	×	×	\checkmark	×	×	\checkmark	\checkmark	\checkmark
Paral Colo	Novo Nordisk	Saxenda	×	×	×	×	\checkmark	×	\checkmark	×	\checkmark	×
liraglutide		Victoza	×	×	×	×	\checkmark	×	\checkmark	\checkmark	x	×
	Novo Nordisk	Wegovy	×	×	×	\checkmark	\checkmark	×	×	×	\checkmark	×
semaglutide		Ozempic	×	×	×	\checkmark	\checkmark	×	×	\checkmark	×	×
		Rybelsus	×	×	×	\checkmark	\checkmark	\checkmark	×	\checkmark	×	×

MANAGEMENT & BOARD OF DIRECTORS





MANAGEMENT TEAM

RUDY MAZZOCCHI Chief Executive Officer

- Seasoned med-tech/biotech entrepreneur and CEO
- Chairman/Director of public & private companies
- Track record of advancing earlystage companies to profitability and exit (M&A or IPO)

MARTIN SCHROEDER Chief Scientific Officer

- Over 25 years of success in general management, technical R&D management, marketing, corporate finance and business development
- Founder of numerous highly valued companies and start-ups

DAVID FIENE Chief Financial Officer

Experienced CFO and Financial Advisor for various Public and Private Companies and Big 4 Public CPA Firms with SEC Compliance responsibilities

Member of American Institute of **Certified Public Accountants**

SALMAN HODA -SVP Portfolio & Bus. Dev.

- Over 18 years of pharma experience
- Experienced in the identification, valuation and negotiation of pharmaceutical assets at various development stages



BOARD OF DIRECTORS

RUDY MAZZOCCHI Chairman & CEO

- Seasoned med-tech/biotech entrepreneur and CEO
- Chairman/Director of public & private companies
- Track record of advancing earlystage companies to profitability and exit (M&A or IPO)

• Co-founder and Director of Green Sky Labs (GSL) Holdings

TWO (2) additional independent directors to be added upon the closing of the next financing

REHAN HUDA Independent Director

• Experienced Investment Banker, **Entrepreneur and Economist**

• Founder of several biotechnology, information technology, and telecommunication companies



SCIENTIFIC ADVISORY BOARD

MARTIN SCHROEDER, MSc Chairman

- Over 25 years of success in general management, technical R&D management, marketing, corporate finance and business development
- Founder of numerous highly valued companies and start-ups

PATRICIA REGGIO, PhD

- Professor of Chemistry & Biochemistry at UNC with expertise in Computational Chemistry and Computer-Aided Drug Design
- Major focus has been on the G proteincoupled cannabinoid receptors;

RANGAN (RONNIE) MAITRA, PhD

- RTI International Research Pharmacologist
- Expertise in the mechanisms of chemotherapy-induced differential regulation of ABC transporters CFTR and P-glycoprotein as well as preclinical drug discovery research related to endocannabinoid receptors;



THANK YOU

